Aehr is in a powerful but extraordinarily unstable uptrend that has recently rolled over into a sharp corrective phase. The stock is up 126.88% over the past year and 173.47% year-to-date, massively outperforming the S&P 500's 15.53% and 11.93% respective gains, yet the current price of $60.60 sits only about 32.6% of the way up its 52-week range of $18.70 to $147.40 — meaning the stock has surrendered roughly two-thirds of its range from the highs despite still being a huge annual winner. That positioning is the classic signature of a momentum name that has broken down: the long-term trend remains intact, but the stock is now testing whether the prior advance was structurally sound or merely a speculative spike.

Short-term momentum is decisively negative and accelerating to the downside. The stock is down 28.07% over the past month and 25.23% over three months, a stark divergence from the +126.88% one-year gain, and the most recent session alone saw a -12.44% drop from $69.21 to $60.60 on elevated volume of roughly 3.5 million shares. Relative strength confirms the deterioration: -29.29% versus SPY over one month and -27.92% over three months, even as the one-year relative strength remains a remarkable +111.35%. This pattern — long-term outperformance colliding with acute short-term underperformance — typically signals either a violent mean-reversion event within an intact uptrend or the early stage of a trend reversal, and the burden of proof now sits with the bulls to defend the $60 area.

Key technical levels are unusually wide given the stock's volatility. Support is anchored near the 52-week low of $18.70, with the more immediately relevant psychological and structural floor around the recent $60.60 close and the July 2026 swing low near $65.40, which has already been breached; resistance sits at the 52-week high of $147.40, with intermediate supply in the $100–$115 zone where the stock repeatedly failed in September and early October. A beta of 3.484 means Aehr is roughly 3.5 times as volatile as the market — a 1% SPY move implies a ~3.5% AEHR move — which, combined with a max drawdown of -58.38%, argues for materially smaller position sizing and wider stops than a typical semiconductor holding. A decisive reclaim of $100 would signal the correction was a shakeout; a sustained break below $60 opens the door toward the $40s and puts the entire 2026 advance in jeopardy.

Aehr's revenue trajectory is inflecting sharply upward after a prolonged trough. The most recent quarter (period ending 2026-05-29) delivered revenue of $19.75 million, up 40.19% year-over-year, a dramatic acceleration from the $10.31 million reported in the prior quarter (Q3 2026) and the $9.88 million in Q2 2026 — both of which had contracted versus the $14.09 million and $18.31 million quarters a year earlier. The sequential jump from ~$10 million to nearly $20 million in a single quarter reflects the AI-driven bookings conversion management has highlighted, with systems contributing $6.76 million, contactors $2.61 million, and services $1.59 million in the disclosed segment split. The investment case now hinges entirely on whether this is the first step of a durable ramp — consensus models roughly $288.1 million in forward revenue, implying more than a tripling from the current run-rate — or a lumpy, one-customer order spike that reverses.

Profitability is thin and inconsistent, though the latest quarter crossed into the black. Net income was $1.39 million (EPS $0.0496) with a 40.6% gross margin and $8.02 million in gross profit, a marked improvement from the -$3.20 million loss and 32.7% gross margin in Q3 2026 and the -$3.23 million loss at 25.7% gross margin in Q2 2026. Still, operating income was -$993,000 and EBITDA -$2.10 million for the quarter, with R&D of $3.65 million and SG&A of $5.58 million consuming most of the gross profit; the trailing net margin remains -14.25% and the operating margin -28.30%. Gross margins have oscillated between roughly 25.7% and 40.6% over four quarters — well below the 50%+ levels Aehr posted in fiscal 2023–2024 — indicating unfavorable product mix and low absorption, and the path to sustainable profitability depends on volume leverage that has not yet materialized.

Balance sheet strength is the company's clearest asset, but cash generation is weak. The current ratio is a fortress-like 10.33, debt-to-equity is just 0.045, and cash reached $116.5 million at the end of the May quarter — boosted by $79.9 million in common stock issuance — providing ample runway. However, trailing free cash flow is -$5.38 million, operating cash flow was only $1.21 million in the latest quarter, and ROE is -3.25% with ROA of -4.47%; the business is not yet self-funding its growth and has relied on equity capital. Inventory days of roughly 317 and a cash conversion cycle near 345 days reflect the long lead times of capital equipment, but they also tie up working capital and make cash flow lumpy — a real risk if the AI order pipeline slips.